

Applicants: David M. Stern et al.
U.S. Serial No.: 09/394,204
Filed: September 10, 1999
Page 2

Amendments to the Claims:

The listing of claims will replace all prior versions and listings of claims in the application:

1-19. (Canceled)

~~120.~~ (Currently Amended) A method for ~~evaluating the ability of~~
~~determining whether~~ an agent ~~to inhibit~~ inhibits binding of
human ERAB polypeptide (SEQ. ID. NO: 2), or a fragment ~~or~~
~~polymorphism~~ thereof, to amyloid-beta peptide which comprises:

- (a) incubating human ERAB polypeptide (SEQ. ID. NO: 2), or
a fragment ~~or polymorphism~~ thereof, the agent and
amyloid-beta peptide under suitable binding
conditions;
- (b) determining the amount of amyloid-beta peptide bound
to the polypeptide, or fragment ~~or polymorphism~~ from
the incubate of (a); and
- (c) comparing the amount of bound amyloid-beta peptide
determined in step (b) to an amount of amyloid-beta
peptide bound to the polypeptide, or fragment ~~or~~
~~polymorphism~~ determined in the absence of the agent,
wherein when the amount of amyloid-beta polypeptide
bound to the polypeptide, or fragment ~~or polymorphism~~
thereof is decreased in the presence of said agent,
the ~~ability of the agent to inhibit~~ inhibits binding
of human ERAB polypeptide (SEQ. ID. NO: 2), or the

OK
12/29/04

Applicants: David M. Stern et al.
U.S. Serial No.: 09/394,204
Filed: September 10, 1999
Page 3

fragment ~~or polymorphism~~ thereof, ~~to amyloid beta is~~
~~determined.~~

21-26. (Canceled)

¹
~~2~~₂₁. (Previously Presented) The method of claim ¹~~20~~₂₀, wherein the agent is a peptide.

¹
~~3~~₂₈. (Previously Presented) The method of claim ¹~~20~~₂₀, wherein the agent is a peptidomimetic compound.

¹
~~4~~₂₉. (Previously Presented) The method of claim ¹~~20~~₂₀, wherein the agent is a nucleic acid.

¹
~~5~~₃₀. (Previously Presented) The method of claim ¹~~20~~₂₀, wherein the agent is a small molecule.